Search

Becton Dickinson and Co

Slēgts

SektorsVeselības aprūpe

183.41 0.86

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

180.71

Max

183.72

Galvenie mērījumi

By Trading Economics

Ienākumi

759M

449M

Pārdošana

269M

5B

P/E

Sektora vidējais

30.601

57.002

EPS

3.23

Dividenžu ienesīgums

2.37

Peļņas marža

9.011

Darbinieki

72,000

EBITDA

-23M

686M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+4.58% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.37%

2.22%

Nākamie ieņēmumi

2026. g. 5. nov.

Nākamais dividenžu datums

2026. g. 30. sept.

Nākamais Ex dividenžu datums

2026. g. 9. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.3B

49B

Iepriekšējā atvēršanas cena

182.55

Iepriekšējā slēgšanas cena

183.41

Ziņu noskaņojums

By Acuity

21%

79%

67 / 340 Rangs Healthcare

Becton Dickinson and Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

2026. g. 13. aug. 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

2026. g. 12. aug. 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

2026. g. 11. aug. 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

2026. g. 10. aug. 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

2026. g. 7. aug. 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

2026. g. 6. aug. 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

2026. g. 5. aug. 19:46 UTC

Becton Dickinson shares are lower today amid broader market declines influenced by ADP's report on private sector job growth miss for July.

2026. g. 4. aug. 23:16 UTC

Becton Dickinson shares higher in after-market trading, reflecting positive market sentiment amid falling crude oil prices and expectations of reduced inflationary pressures.

2026. g. 3. aug. 22:51 UTC

Becton Dickinson shares are lower in after-market trading, influenced by a significant downturn in the Health Care Equipment sub-sector.

2026. g. 31. jūl. 19:46 UTC

Becton Dickinson is higher today, showing resilience amid rising bond yields and inflation concerns. The stock remains above its 20-day moving average.

2026. g. 30. jūl. 22:51 UTC

Becton Dickinson and Co shares are lower in after-hours trading, reflecting broader weakness in the Health Care Equipment sub-sector.

2026. g. 29. jūl. 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

2026. g. 28. jūl. 20:02 UTC

News

UBS initiated coverage of Becton Dickinson with a Buy rating and $190 price target, contributing to the stock's upward movement this week.

2026. g. 27. jūl. 20:06 UTC

Becton Dickinson shares are higher, reflecting strength near the upper end of their one-month range amid falling oil prices and declining Treasury yields.

2026. g. 24. jūl. 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

2026. g. 23. jūl. 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

2026. g. 21. jūl. 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

2026. g. 20. jūl. 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Salīdzinājums

Cenas izmaiņa

Becton Dickinson and Co Prognoze

Cenas mērķis

By TipRanks

4.58% augšup

Prognoze 12 mēnešiem

Vidējais 191.8 USD  4.58%

Augstākais 210 USD

Zemākais 175 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Becton Dickinson and Co — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

5

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

67 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat